| Literature DB >> 34504351 |
Jonathan Foox1,2, Scott W Tighe3, Charles M Nicolet4, Justin M Zook5, Marta Byrska-Bishop6, Wayne E Clarke6, Michael M Khayat7,8, Medhat Mahmoud7,8, Phoebe K Laaguiby3, Zachary T Herbert9, Derek Warner10, George S Grills11, Jin Jen12, Shawn Levy13, Jenny Xiang1, Alicia Alonso1, Xia Zhao14,15, Wenwei Zhang14, Fei Teng14, Yonggang Zhao14,16, Haorong Lu14,17, Gary P Schroth18, Giuseppe Narzisi6, William Farmerie19, Fritz J Sedlazeck20,21, Don A Baldwin22, Christopher E Mason23,24,25,26.
Abstract
Assessing the reproducibility, accuracy and utility of massively parallel DNA sequencing platforms remains an ongoing challenge. Here the Association of Biomolecular Resource Facilities (ABRF) Next-Generation Sequencing Study benchmarks the performance of a set of sequencing instruments (HiSeq/NovaSeq/paired-end 2 × 250-bp chemistry, Ion S5/Proton, PacBio circular consensus sequencing (CCS), Oxford Nanopore Technologies PromethION/MinION, BGISEQ-500/MGISEQ-2000 and GS111) on human and bacterial reference DNA samples. Among short-read instruments, HiSeq 4000 and X10 provided the most consistent, highest genome coverage, while BGI/MGISEQ provided the lowest sequencing error rates. The long-read instrument PacBio CCS had the highest reference-based mapping rate and lowest non-mapping rate. The two long-read platforms PacBio CCS and PromethION/MinION showed the best sequence mapping in repeat-rich areas and across homopolymers. NovaSeq 6000 using 2 × 250-bp read chemistry was the most robust instrument for capturing known insertion/deletion events. This study serves as a benchmark for current genomics technologies, as well as a resource to inform experimental design and next-generation sequencing variant calling.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34504351 PMCID: PMC8985210 DOI: 10.1038/s41587-021-01049-5
Source DB: PubMed Journal: Nat Biotechnol ISSN: 1087-0156 Impact factor: 54.908